The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the armed forces regression study

American Journal of the Medical Sciences

Volumn 341, Issue 5, 2011, Pages 378-382

  Krasuski, Richard A ^a   Devendra, Ganesh P ^a   Cater, George ^a   Whitney, Edwin J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b San Antonio Endovascular and Heart Institute   (United States)

Author keywords

Diabetes; Exercise; HDL; Metabolic syndrome

Indexed keywords

COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ARTICLE; CALORIC RESTRICTION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FLUSHING; HEART INFARCTION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 79955521241     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318209d851     Document Type: Article

References (18)

1. Khan LK, Sobush K, Keener D, et al. Recommended community strategies and measurements to prevent obesity in the United States. MMWR Recomm Rep 2009;58:1-26.
2. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
3. Pereira MA, Kartashov AI, Ebbeling CB, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005;365:36-42. (Pubitemid 40082144)
4. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481-6.
5. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-32.
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9. (Pubitemid 32893993)
7. Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective populationbased study in Finnish subjects. Diabetes Care 2005;28:2901-7. (Pubitemid 43942922)
8. Lempiainen P, Mykkanen L, Pyorala K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-8. (Pubitemid 29330009)
9. Wagh A, Stone NJ. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther 2004;2:213-28. (Pubitemid 38713916)
10. Pasanisi F, Contaldo F, de Simone G, et al. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001;11: 401-6. (Pubitemid 33689025)
11. Pacholczyk M, Ferenc T, Kowalski J. [Metabolic syndrome. Part III: its prevention and therapeutic management]. Postepy Hig Med Dosw (Online) 2008;62:559-70.
12. Singh RB, Singh NK, Rastogi SS, et al. Effects of diet and lifestyle changes on atherosclerotic risk factors after 24 weeks on the Indian Diet Heart Study. Am J Cardiol 1993;71:1283-8. (Pubitemid 23156681)
13. Anderssen SA, Hjermann I, Urdal P, et al. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome." Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med 1996;240:203-9. (Pubitemid 26356042)
14. Fappa E, Yannakoulia M, Pitsavos C, et al. Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues? Nutrition 2008;24:286-91.
15. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.
16. Jiamsripong P, Mookadam M, Alharthi MS, et al. The metabolic syndrome and cardiovascular disease: part 2. Prev Cardiol 2008;11: 223-9.
17. Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol 2003;92: 50-4. (Pubitemid 36782309)
18. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000;140:631-6.